Targeted Therapy and Avelumab in Merkel Cell Carcinoma
Status:
Recruiting
Trial end date:
2024-01-01
Target enrollment:
Participant gender:
Summary
10.17 GoTHAM is intended as a signal-seeking, biomarker, phase Ib/II study that will evaluate
the safety and anti-tumour activities of the novel combination of avelumab with
177-Lu-DOTATATE (a type of peptide receptor radionuclide therapy; PRRT) or external beam
radiation therapy (EBRT) in patients with metastatic Merkel cell carcinoma (mMCC).
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Melanoma and Skin Cancer Trials Limited
Treatments:
Antibodies, Monoclonal Avelumab Lutetium Lu 177 dotatate